"What impresses me is the consistency, the safety and the efficacy of this device."

— Michael O'Donnell, director of urological oncology at the University of Iowa Hospitals and Clinics, discussing the Synergo, a radio frequency ablation catheter that was the subject of an FDA advisory committee session this week, "Synergo PMA backed by panel with only outside-U.S. data," pp. 1, 6.